SCHEMBL3526280

SCHEMBL3526280

Cc1ccnc2c(C(=O)O)cccc12

nearest known ligand 0.54

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PSMD14 O00487 3/20 0.54
COPS5 Q92905 2/20 0.54
KDM4E B2RXH2 6/20 0.54
L3MBTL1 Q9Y468 3/20 0.54
KDM4A O75164 2/20 0.54
EGLN1 Q9GZT9 2/20 0.54
RAB9A P51151 1/20 0.54
HIF1AN Q9NWT6 1/20 0.54
CCR1 P32246 2/20 0.52
CCR5 P51681 2/20 0.52
CCR8 P51685 2/20 0.52
KDM6B O15054 1/20 0.46
KDM6A O15550 1/20 0.46
TET3 O43151 1/20 0.46
KDM4B O94953 1/20 0.46
KDM5C P41229 1/20 0.46
KDM4D Q6B0I6 1/20 0.46
TET2 Q6N021 1/20 0.46
ALKBH5 Q6P6C2 1/20 0.46
TET1 Q8NFU7 1/20 0.46

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL29903982 1.00 PSMD14 (0.54) PSMD14COPS5KDM4EL3MBTL1KDM4A
SCHEMBL2134700 0.98 PSMD14 (0.53) PSMD14COPS5KDM4EL3MBTL1KDM4A
SCHEMBL27610054 0.98 PSMD14 (0.53) PSMD14COPS5KDM4EL3MBTL1KDM4A
SCHEMBL30503371 0.86 SLC6A2 (0.59) PSMD14COPS5KDM4EL3MBTL1KDM4A
SCHEMBL11803761 0.86 SLC6A2 (0.59) PSMD14COPS5KDM4EL3MBTL1KDM4A
SCHEMBL27575501 0.85 SLC6A2 (0.57) PSMD14COPS5KDM4EL3MBTL1KDM4A
SCHEMBL69905 0.84 KDM4E (0.74) PSMD14KDM4EL3MBTL1KDM4AEGLN1
Lithium Ion SCHEMBL17474361 0.83 PSMD14 (0.51) PSMD14COPS5KDM4EL3MBTL1KDM4A
SCHEMBL2538502 0.83 PSMD14 (0.51) PSMD14COPS5KDM4EL3MBTL1KDM4A
SCHEMBL537470 0.83 PSMD14 (0.51) PSMD14COPS5KDM4EL3MBTL1KDM4A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230330099-A1 SUBSTITUTED INDOLE MCL-1 INHIBITORS VANDERBILT UNIVERSITY 2023-10-19 US disclosed
US-7645771-B2 CCR5 antagonists as therapeutic agents SMITHKLINE BEECHAM CORP. (US) 2010-01-12 US disclosed
US-20080124732-A1 METHOD FOR OPTICAL MEASUREMENT OF MULTI-STRANDED NUCLEIC ACID FUJIFILM CORPORATION 2008-05-29 US disclosed
EP-1889880-A2 Method for optical measurement of multi-stranded nucleic acid FUJIFILM Corporation (JP) 2008-02-20 EP disclosed
EP-1362894-B1 Method for optical measurement of multi-stranded nucleic acid using cyanine dyes FUJIFILM CORP (JP) 2007-12-19 EP disclosed
US-20060229336-A1 Ccr5 antagonists as therapeutic agents SMITHKLINE BEECHAM CORPORATION 2006-10-12 US disclosed
CN-1744899-A Piperidine derivatives as CCR5 antagonists SMITHKLINE BEECHAM CORP (US) 2006-03-08 CN disclosed
EP-1569646-A2 PIPERIDINE DERIVATIVES AS CCR5 ANTAGONISTS SMITHKLINE BEECHAM CORPORATION (US) 2005-09-07 EP disclosed
US-20050112770-A1 Method for optical measurement of multi-stranded nucleic acid FUJI PHOTO FILM CO., LTD. 2005-05-26 US disclosed
CN-1575068-A Light emitting material, method of manufacturing the light emitting material and method of manufacturing light emitting layer SEIKO EPSON CORP (JP) 2005-02-02 CN disclosed
WO-2004054974-A2 PIPERIDINE DERIVATIVES AS CCR5 ANTAGONISTS SMITHKLINE BEECHAM CORPORATION (US) 2004-07-01 WO disclosed
EP-1362894-A2 Method for optical measurement of multi-stranded nucleic acid using cyanine dyes FUJI PHOTO FILM CO., LTD. (JP) 2003-11-19 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230330099-A1 SUBSTITUTED INDOLE MCL-1 INHIBITORS MCL1, BCL2L1, BCL9 PSMD14 2311/4885COPS5 3658/4885KDM4E 1156/4885
US-20060229336-A1 Ccr5 antagonists as therapeutic agents CCR5, CCR1, CXCR3 PSMD14 4563/4885COPS5 2280/4885KDM4E 4644/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.